Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

NCT05176080 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

46

Enrollment

OTHER_GOV

Sponsor class

Stopped Investigators' decision

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Famitinib
DRUG: SHR6390
DRUG: Fulvestrant

Sponsor

Henan Cancer Hospital